Ralaniten
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | EPI-002 |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H27ClO5 |
Molar mass | 394.89 g·mol−1 |
3D model (JSmol) | |
| |
|
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed.[1] It is a derivative of bisphenol A[2] and one of the four stereoisomers of EPI-001.[1] A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.[3]
See also
References
- ^ a b Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. (July 2013). "An androgen receptor N-terminal domain antagonist for treating prostate cancer". The Journal of Clinical Investigation. 123 (7): 2948–2960. doi:10.1172/JCI66398. PMC 3696543. PMID 23722902.
- ^ Monaghan AE, McEwan IJ (2016). "A sting in the tail: the N-terminal domain of the androgen receptor as a drug target". Asian Journal of Andrology. 18 (5): 687–694. doi:10.4103/1008-682X.181081. PMC 5000789. PMID 27212126.
- ^ Maughan BL, Antonarakis ES (December 2015). "Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer". Current Treatment Options in Oncology. 16 (12): 57. doi:10.1007/s11864-015-0375-z. PMID 26537882. S2CID 30398927.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Alkylating agents
- 2,2-Bis(4-hydroxyphenyl)propanes
- Halohydrins
- Nonsteroidal antiandrogens
- Organochlorides
- Polyols
- Glycerols
- All stub articles
- Antineoplastic and immunomodulating drug stubs
- Genito-urinary system drug stubs